A
Agile Therapeutics Inc
F:0AL
Agile Therapeutics Inc
F:0AL
Price:
1.11
EUR
-1.77%
Market Cap:
€9.3m
Balance Sheet
Balance Sheet Decomposition
Agile Therapeutics Inc
Agile Therapeutics Inc
Balance Sheet Decomposition is not available for
Agile Therapeutics Inc
Agile Therapeutics Inc
Balance Sheet
Agile Therapeutics Inc
Agile Therapeutics Inc
Currency: USD
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
40
|
34
|
49
|
36
|
8
|
34
|
14
|
19
|
5
|
3
|
|
| Cash Equivalents |
40
|
34
|
49
|
36
|
8
|
34
|
14
|
19
|
5
|
3
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
40
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
3
|
3
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
3
|
3
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
3
|
|
| Other Current Assets |
1
|
4
|
3
|
1
|
1
|
1
|
1
|
2
|
1
|
1
|
|
| Total Current Assets |
41
|
38
|
52
|
37
|
8
|
35
|
57
|
24
|
11
|
10
|
|
| PP&E Net |
12
|
12
|
12
|
14
|
14
|
14
|
14
|
13
|
1
|
0
|
|
| PP&E Gross |
12
|
12
|
0
|
14
|
14
|
14
|
14
|
13
|
1
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
|
| Other Long-Term Assets |
2
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
2
|
0
|
|
| Total Assets |
55
N/A
|
50
-8%
|
64
+27%
|
51
-21%
|
22
-56%
|
50
+121%
|
73
+47%
|
39
-46%
|
14
-64%
|
10
-28%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
3
|
2
|
2
|
3
|
1
|
2
|
4
|
9
|
8
|
10
|
|
| Accrued Liabilities |
1
|
3
|
4
|
1
|
1
|
2
|
3
|
4
|
4
|
9
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
5
|
2
|
5
|
11
|
0
|
0
|
0
|
17
|
1
|
2
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
9
|
8
|
11
|
14
|
2
|
4
|
7
|
29
|
13
|
21
|
|
| Long-Term Debt |
10
|
13
|
11
|
0
|
0
|
0
|
16
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
6
|
6
|
|
| Total Liabilities |
19
N/A
|
21
+10%
|
22
+4%
|
14
-34%
|
2
-84%
|
4
+71%
|
24
+524%
|
30
+27%
|
20
-34%
|
27
+34%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
134
|
165
|
193
|
222
|
242
|
260
|
312
|
387
|
409
|
423
|
|
| Additional Paid In Capital |
170
|
194
|
236
|
258
|
262
|
306
|
362
|
396
|
403
|
407
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
36
N/A
|
30
-17%
|
42
+42%
|
36
-14%
|
20
-44%
|
46
+127%
|
49
+8%
|
9
-81%
|
6
N/A
|
16
-194%
|
|
| Total Liabilities & Equity |
55
N/A
|
50
-8%
|
64
+27%
|
51
-21%
|
22
-56%
|
50
+121%
|
73
+47%
|
39
-46%
|
14
-64%
|
10
-28%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
